Abstract
Summary
Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
The global Celecoxib market is projected to reach US$ 2250.6 million by 2030 from an estimated US$ 1387.2 million in 2024, at a CAGR of 8.4% during 2024 and 2030.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Celecoxib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Celecoxib.
The Celecoxib market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Celecoxib market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Celecoxib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.
Market Segmentation
By Company
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
Segment by Type
50mg
100mg
200mg
400mg
Segment by Application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Celecoxib in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Celecoxib manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Celecoxib sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
The global Celecoxib market is projected to reach US$ 2250.6 million by 2030 from an estimated US$ 1387.2 million in 2024, at a CAGR of 8.4% during 2024 and 2030.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Celecoxib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Celecoxib.
The Celecoxib market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Celecoxib market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Celecoxib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.
Market Segmentation
By Company
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
Segment by Type
50mg
100mg
200mg
400mg
Segment by Application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Celecoxib in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Celecoxib manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Celecoxib sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Table of Contents
1 Study Coverage
1.1 Celecoxib Product Introduction
1.2 Market by Type
1.2.1 Global Celecoxib Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 50mg
1.2.3 100mg
1.2.4 200mg
1.2.5 400mg
1.3 Market by Application
1.3.1 Global Celecoxib Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Rheumatoid arthritis
1.3.3 osteoarthritis
1.3.4 Acute pain
1.3.5 Musculoskeletal pain
1.3.6 Other diseases
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Celecoxib Market Size Estimates and Forecasts
2.1.1 Global Celecoxib Revenue 2019-2030
2.1.2 Global Celecoxib Sales 2019-2030
2.2 Celecoxib Market Size by Region: 2023 Versus 2030
2.3 Celecoxib Sales by Region (2019-2030)
2.3.1 Global Celecoxib Sales by Region: 2019-2024
2.3.2 Global Celecoxib Sales Forecast by Region (2025-2030)
2.3.3 Global Celecoxib Sales Market Share by Region (2019-2030)
2.4 Celecoxib Market Estimates and Projections by Region (2025-2030)
2.4.1 Global Celecoxib Revenue by Region: 2019-2024
2.4.2 Global Celecoxib Revenue Forecast by Region (2025-2030)
2.4.3 Global Celecoxib Revenue Market Share by Region (2019-2030)
3 Global Celecoxib by Manufacturers
3.1 Global Top Celecoxib Manufacturers by Sales
3.1.1 Global Celecoxib Sales by Manufacturer (2019-2024)
3.1.2 Global Celecoxib Sales Market Share by Manufacturer (2019-2024)
3.2 Global Top Celecoxib Manufacturers by Revenue
3.2.1 Global Celecoxib Revenue by Manufacturer (2019-2024)
3.2.2 Global Celecoxib Revenue Share by Manufacturer (2019-2024)
3.3 Global Celecoxib Price by Manufacturer (2019-2024)
3.4 Competitive Landscape
3.4.1 Key Celecoxib Manufacturers Covered: Ranking by Revenue
3.4.2 Global Celecoxib Market Concentration Ratio (CR5 and HHI) & (2019-2024)
3.4.3 Global Celecoxib Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Celecoxib Manufacturing Base Distribution, Product Type
3.5.1 Celecoxib Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Celecoxib Product Type
3.5.3 Date of International Manufacturers Enter into Celecoxib Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Pfizer Inc
4.1.1 Pfizer Inc Company Information
4.1.2 Pfizer Inc Description, Business Overview
4.1.3 Pfizer Inc Celecoxib Products Offered
4.1.4 Pfizer Inc Celecoxib Sales, Revenue and Gross Margin (2019-2024)
4.1.5 Pfizer Inc Celecoxib Sales by Product in 2023
4.1.6 Pfizer Inc Celecoxib Sales by Application in 2023
4.1.7 Pfizer Inc Celecoxib Sales by Geographic Area in 2023
4.1.8 Pfizer Inc Recent Developments
4.2 Teva
4.2.1 Teva Company Information
4.2.2 Teva Description, Business Overview
4.2.3 Teva Celecoxib Products Offered
4.2.4 Teva Celecoxib Sales, Revenue and Gross Margin (2019-2024)
4.2.5 Teva Celecoxib Sales by Product in 2023
4.2.6 Teva Celecoxib Sales by Application in 2023
4.2.7 Teva Celecoxib Sales by Geographic Area in 2023
4.2.8 Teva Recent Developments
4.3 Mylan
4.3.1 Mylan Company Information
4.3.2 Mylan Description, Business Overview
4.3.3 Mylan Celecoxib Products Offered
4.3.4 Mylan Celecoxib Sales, Revenue and Gross Margin (2019-2024)
4.3.5 Mylan Celecoxib Sales by Product in 2023
4.3.6 Mylan Celecoxib Sales by Application in 2023
4.3.7 Mylan Celecoxib Sales by Geographic Area in 2023
4.3.8 Mylan Recent Developments
4.4 Apotex
4.4.1 Apotex Company Information
4.4.2 Apotex Description, Business Overview
4.4.3 Apotex Celecoxib Products Offered
4.4.4 Apotex Celecoxib Sales, Revenue and Gross Margin (2019-2024)
4.4.5 Apotex Celecoxib Sales by Product in 2023
4.4.6 Apotex Celecoxib Sales by Application in 2023
4.4.7 Apotex Celecoxib Sales by Geographic Area in 2023
4.4.8 Apotex Recent Developments
4.5 Lupin
4.5.1 Lupin Company Information
4.5.2 Lupin Description, Business Overview
4.5.3 Lupin Celecoxib Products Offered
4.5.4 Lupin Celecoxib Sales, Revenue and Gross Margin (2019-2024)
4.5.5 Lupin Celecoxib Sales by Product in 2023
4.5.6 Lupin Celecoxib Sales by Application in 2023
4.5.7 Lupin Celecoxib Sales by Geographic Area in 2023
4.5.8 Lupin Recent Developments
4.6 Hengrui Medicine
4.6.1 Hengrui Medicine Company Information
4.6.2 Hengrui Medicine Description, Business Overview
4.6.3 Hengrui Medicine Celecoxib Products Offered
4.6.4 Hengrui Medicine Celecoxib Sales, Revenue and Gross Margin (2019-2024)
4.6.5 Hengrui Medicine Celecoxib Sales by Product in 2023
4.6.6 Hengrui Medicine Celecoxib Sales by Application in 2023
4.6.7 Hengrui Medicine Celecoxib Sales by Geographic Area in 2023
4.6.8 Hengrui Medicine Recent Development
5 Breakdown Data by Type
5.1 Global Celecoxib Sales by Type (2019-2030)
5.1.1 Global Celecoxib Sales by Type (2019-2024)
5.1.2 Global Celecoxib Sales Forecast by Type (2025-2030)
5.1.3 Global Celecoxib Sales Market Share by Type (2019-2030)
5.2 Global Celecoxib Revenue Forecast by Type (2019-2030)
5.2.1 Global Celecoxib Revenue by Type (2019-2024)
5.2.2 Global Celecoxib Revenue Forecast by Type (2025-2030)
5.2.3 Global Celecoxib Revenue Market Share by Type (2019-2030)
5.3 Celecoxib Average Selling Price (ASP) by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Celecoxib Sales by Application (2019-2030)
6.1.1 Global Celecoxib Sales by Application (2019-2024)
6.1.2 Global Celecoxib Sales Forecast by Application (2025-2030)
6.1.3 Global Celecoxib Sales Market Share by Application (2019-2030)
6.2 Global Celecoxib Revenue Forecast by Application (2019-2030)
6.2.1 Global Celecoxib Revenue by Application (2019-2024)
6.2.2 Global Celecoxib Revenue Forecast by Application (2025-2030)
6.2.3 Global Celecoxib Revenue Market Share by Application (2019-2030)
6.3 Celecoxib Average Selling Price (ASP) by Application (2019-2030)
7 North America
7.1 North America Celecoxib Market Size YoY Growth 2019-2030
7.2 North America Celecoxib Market Facts & Figures by Country
7.2.1 North America Celecoxib Sales by Country (2019-2030)
7.2.2 North America Celecoxib Revenue by Country (2019-2030)
7.3 North America Celecoxib Sales by Type (2019-2024)
7.4 North America Celecoxib Sales by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Celecoxib Market Size YoY Growth 2019-2030
8.2 Asia-Pacific Celecoxib Market Facts & Figures by Region
8.2.1 Asia-Pacific Celecoxib Sales by Region (2019-2030)
8.2.2 Asia-Pacific Celecoxib Revenue by Region (2019-2030)
8.3 Asia-Pacific Celecoxib Sales by Type (2019-2024)
8.4 Asia-Pacific Celecoxib Sales by Application (2019-2024)
9 Europe
9.1 Europe Celecoxib Market Size YoY Growth 2019-2030
9.2 Europe Celecoxib Market Facts & Figures by Country
9.2.1 Europe Celecoxib Sales by Country (2019-2030)
9.2.2 Europe Celecoxib Revenue by Country (2019-2030)
9.3 Europe Celecoxib Sales by Type (2019-2024)
9.4 Europe Celecoxib Sales by Application (2019-2024)
10 Latin America
10.1 Latin America Celecoxib Market Size YoY Growth 2019-2030
10.2 Latin America Celecoxib Market Facts & Figures by Country
10.2.1 Latin America Celecoxib Sales by Country (2019-2030)
10.2.2 Latin America Celecoxib Revenue by Country (2019-2030)
10.3 Latin America Celecoxib Sales by Type (2019-2024)
10.4 Latin America Celecoxib Sales by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Celecoxib Market Size YoY Growth 2019-2030
11.2 Middle East and Africa Celecoxib Market Facts & Figures by Country
11.2.1 Middle East and Africa Celecoxib Sales by Country (2019-2030)
11.2.2 Middle East and Africa Celecoxib Revenue by Country (2019-2030)
11.3 Middle East and Africa Celecoxib Sales by Type (2019-2024)
11.4 Middle East and Africa Celecoxib Sales by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Celecoxib Supply Chain Analysis
12.2 Celecoxib Key Raw Materials and Upstream Suppliers
12.3 Celecoxib Clients Analysis
12.4 Celecoxib Sales Channel and Sales Model Analysis
12.4.1 Celecoxib Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Celecoxib Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Celecoxib Distributors
13 Market Dynamics
13.1 Celecoxib Industry Trends
13.2 Celecoxib Market Drivers
13.3 Celecoxib Market Challenges
13.4 Celecoxib Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer